期刊
FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.618737
关键词
kidney transplantation; Belatacept; acute rejection; BTLA; CTLA-4; immunosuppressant
类别
资金
- National Natural Science Foundation of China [82070769, 81900684, 81870512, 81770751, 81570676, 81470981, 81100532]
- Project of Jiangsu Province for Important Medical Talent [ZDRCA2016025]
- 333 High Level Talents Project in Jiangsu Province [BRA2017532, BRA2016514, BRA2015469]
- Standardized Diagnosis and Treatment Research Program of Key Diseases in Jiangsu Province [BE2016791]
- Open Project Program of Health Department of Jiangsu Province [JSY-2-2016-099]
- Jiangsu Province Natural Science Foundation Program [BK20191063]
This study demonstrates that combined therapy of Belatacept and BTLA overexpression effectively attenuates acute rejection after kidney transplantation and prolongs kidney graft survival. The therapy reduces serum creatinine levels, inhibits mixed acute rejection, decreases DSA production, and modulates cytokine expression. The duration of elevated expression levels of CTLA-4 and BTLA differentially affects the immune response.
Background Costimulatory blockade provides new therapeutic opportunities for ensuring the long-term survival of kidney grafts. The adoption of the novel immunosuppressant Belatacept has been limited, partly due to concerns regarding higher rates and grades of acute rejection in clinical trials. In this study, we hypothesized that a combined therapy, Belatacept combined with BTLA overexpression, may effectively attenuate acute rejection after kidney transplantation. Materials and Methods The rat kidney transplantation model was used to investigate graft rejection in single and combined therapy. Graft function was analyzed by detecting serum creatinine. Pathological staining was used to observe histological changes in grafts. The expression of T cells was observed by immunohistochemistry and flow cytometry. In vitro, we constructed an antigen-stimulated immune response by mixed lymphocyte culture, treated with or without Belatacept and BTLA-overexpression adenovirus, to observe the proliferation of receptor cells and the expression of cytokines. In addition, western blot and qRT-PCR analyses were performed to evaluate the expression of CTLA-4 and BTLA at various time points during the immune response. Results In rat models, combined therapy reduced the serum creatinine levels and prolonged graft survival compared to single therapy and control groups. Mixed acute rejection was shown in the allogeneic group and inhibited by combination treatment. Belatacept reduced the production of DSA and the deposition of C4d in grafts. Belatacept combined with BTLA overexpression downregulated the secretion of IL-2 and IFN-gamma, as well as increasing IL-4 and IL-10 expression. We also found that Belatacept combined with BTLA overexpression inhibited the proliferation of spleen lymphocytes. The duration of the elevated expression levels of CTLA-4 and BTLA differentially affected the immune response. Conclusion Belatacept combined with BTLA overexpression attenuated acute rejection after kidney transplantation and prolonged kidney graft survival, which suggests a new approach for the optimization of early immunosuppression after kidney transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据